MedTrace Logo

The Effects of NOx and Conjugated Linoleic Acid on Asthmatics

NCT02433977 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2021-04-27

Study results available
· View outcomes & findings →

Summary

This study will examine the hypothesis that in obese asthmatics; treatment with NOx + CLA is well tolerated, safe and will increase eNO while reducing airway oxidative stress. Allied with this, the investigators will define whether supplementing with this bioactive mediator modifies the airway microbiome, and reduces airway inflammation.

Conditions

Interventions

DIETARY_SUPPLEMENT

Conjugated Linolenic Acid

CLA is a polyunsaturated fatty acid Subjects will receive capsules for daily oral administration at the dose of 3 g/day

DRUG

Sodium Nitrite

Subjects will receive capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)

DRUG

Sodium Nitrate

Subjects will receive capsules for daily oral administration at the dose of 1g (2 x 500 mg)

Sponsors & Collaborators

  • Gladwin, Mark, MD

    lead INDIV

Principal Investigators

  • Sally E Wenzel, MD · The University of Pittsburgh Asthma Institute at UPMC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2019-11-30
Completion
2019-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02433977 on ClinicalTrials.gov